We currently have the knowledge and experience to prevent much of human papillomavirus
(HPV)-related disease burden globally. In many countries where prophylactic HPV …

Human papillomavirus (HPV) infections continue to be one of the most common sexually
transmitted infections worldwide. The oncogenic potential of this virus was well established …

Human papilloma virus (HPV) vaccination has been implemented in several countries for
about the past 7 years, mainly in the adolescent female population, with varying coverage …

Human papillomavirus (HPV) is the causative agent in cervical cancer and has been
implicated in a range of other malignancies. Preventative vaccines are now internationally …

Ten years after the first licencing of a prophylactic human papillomavirus (HPV) vaccine, this
paper reviews global information on programme coverage, as reported to WHO and from the …

Since 2006, 115 countries and territories have introduced human papillomavirus (HPV)
vaccination programs. Several efforts have been undertaken to evaluate the impact of HPV …

The availability of prophylactic human papillomavirus (HPV) vaccines has provided powerful
tools for primary prevention of cervical cancer and other HPV-associated diseases. Since …

Background and aim: Human papillomavirus (HPV) is sexually transmitted, one of the three
most common sexually transmitted infections (STIs) in both males and females, and the most …

Prophylactic vaccines for human papillomavirus (HPV) are being introduced in many
countries for the prevention of cervical cancer, the second most important cause of cancer …

Cervical cancer incidence and mortality have decreased in high-income countries, but low-
and middle-income countries continue to bear a significant burden from the disease. Human …